Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Skyrizi Market Value Analysis: What Growth Lies Ahead Over The Forecast Period?
The historical period’s growth stemmed from a rise in autoimmune disorder diagnoses, the drawbacks of conventional immunosuppressive treatments, greater integration of biologics in dermatology and gastroenterology, increased access to specialty care, and improving clinical trial success rates.
Anticipated growth during the projection period stems from expanding into additional inflammatory conditions, heightened financial commitment to advanced biologics, an increasing patient demand for user-friendly dosing schedules, a strengthened healthcare emphasis on achieving lasting remission, and the broadening of guidelines for biologic therapies.
Significant trends for the projection period involve greater uptake of therapies targeting IL-23, expanded application across various autoimmune conditions, an escalating preference for biologics with extended dosing intervals, the proliferation of self-injectable formats, and a magnified emphasis on managing diseases over the long term.
Get A Free Sample Report With In-Depth Market Insights:
Skyrizi Market Development Factors: What’s Supporting Demand?
The skyrizi market is anticipated to grow as a result of the rising interest in personalized medicine. This medical methodology tailors treatment and healthcare strategies to individual patient characteristics, including their genetic composition, surroundings, and lifestyle, to achieve the most effective and precise outcomes. The expansion of personalized medicine is driven by advancements in genomic technologies, an enhanced understanding of molecular biology, the increasing availability of precision diagnostic instruments, and the demand for targeted therapies that improve patient results while minimizing adverse reactions. Skyrizi contributes to personalized medicine by offering a targeted biologic therapy that specifically inhibits interleukin-23 (IL-23), allowing healthcare providers to customize treatment for patients with moderate to severe autoimmune conditions, such as psoriasis and ulcerative colitis, based on individual responses and disease characteristics, thereby improving efficacy and reducing treatment-related side effects. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based hospital and health care organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, an increase from six in 2022. Therefore, the expanding interest in personalized medicine significantly propels the skyrizi market.
Skyrizi Market Segment Analysis Spotlighting Growth Areas
The skyrizi market covered in this report is segmented –
1) By Indication: Plaque Psoriasis, Crohn’s Disease, Ulcerative Colitis
2) By Formulation: Pre-Filled Syringes, Vials
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Skyrizi Market Transformation Trends: What Innovations Are Driving Change?
Companies operating in the SKYRIZI market are concentrating on developing innovative solutions, such as interleukin-23 (IL-23) inhibitor therapies, to address the increasing demand for targeted and highly effective treatments for autoimmune and chronic inflammatory diseases. IL-23 inhibitors function by selectively blocking the p19 subunit of the IL-23 cytokine, a key factor in driving inflammatory pathways. This focused approach provides enhanced efficacy and safety compared to traditional broad-spectrum immunosuppressants. For example, in July 2024, AbbVie Inc., a US-based biopharmaceutical company, obtained European Commission approval for SKYRIZI (risankizumab) for the treatment of adults with moderately to severely active ulcerative colitis who have been unresponsive or intolerant to conventional or biologic therapies. SKYRIZI is a monoclonal antibody that precisely inhibits IL-23, offering a specific mechanism of action that assists in reducing inflammation and promoting mucosal healing. The therapy includes a 1,200 mg IV induction regimen, followed by 180 mg or 360 mg subcutaneous maintenance doses administered every eight weeks. Clinical data from the Phase 3 INSPIRE and COMMAND trials showcased robust outcomes, including significant mucosal healing and sustained remission, particularly in patients without prior biologic or JAK inhibitor use.
Skyrizi Market Leading Companies: Who Holds The Strongest Market Presence?
Major companies operating in the skyrizi market are AbbVie Inc.
View The Full Skyrizi Market Report:
Skyrizi Market Geographic Analysis: Where Is Demand Rising Fastest?
North America was the largest region in the skyrizi market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the skyrizi market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
